Elon Musk‘s ambitious venture, Neuralink, recently made headlines as the tech entrepreneur claimed that the startup successfully implanted its brain-machine interface device in a live human subject.
Musk’s announcement, while met with scepticism given his history of ambitious promises, followed months of rigorous scrutiny and approval processes, shedding light on the company’s journey to conduct human trials.
The pivotal moment came when Neuralink received approval from the Food and Drug Administration (FDA) to initiate human clinical trials, marking a significant milestone for the company. The FDA approval underscores the adherence to stringent standards designed to safeguard human subjects in medical trials, even as social media buzzed with reminders of past tech hiccups at Musk’s other ventures, Tesla and SpaceX.
Read Also: Chita Rivera died at the age of 91
What is Neuralink?
Founded in 2016 by Musk and a team of neuroscientists, Neuralink’s mission centres around developing and marketing an implantable brain-computer interface device. The current design of the device, described as “cosmetically invisible,” involves a lithium battery, small computer chips, and other electronics. The implantation process is carried out by a surgical robot equipped with cameras, sensors, and a needle thinner than a human hair.
Neuralink work?
Neuralink has positioned its technology not only as a potential treatment for neurological diseases but also as a means of augmenting human biology and integrating it with machines and artificial intelligence. Musk’s vision extends to a product named “Telepathy,” the first offering from Neuralink, which aims to enable users, particularly those with limb loss, to control devices like phones and computers through thought alone.
How Neuralink Got FDA Approval for Human Trials
However, the road to FDA approval for Neuralink was not without obstacles. Internal staff complaints about the mistreatment of animals and concerns about potential human exposure to infectious pathogens through contaminated hardware prompted investigations, raising ethical questions about the company’s practices.
Neuralink’s journey through the FDA approval process involved overcoming a denial of an “investigational device exemption” (IDE) earlier in 2023, with reasons for the initial denial undisclosed.
The IDE application requires a detailed report on prior experiments, including animal testing, a comprehensive description of the device, and a plan for human trials. The FDA reserves the right to pause or terminate a clinical trial if it deviates from the approved application or poses serious harm to participants.
The final and most stringent step for a Class III device like Neuralink’s brain implant is the premarket approval (PMA) process, where FDA scientists meticulously scrutinize trial results and other aspects of the application before granting approval for market release. Even with approval, certain patient groups may be excluded, and usage limitations may be imposed based on distinct medical needs.
Read Also: Newcastle Hands Aston Villa First Premier League Home Defeat in Almost a Year with a 3-1 Victory
Are other companies doing the same thing as Neuralink?
While Neuralink’s progress is grabbing headlines, it’s essential to note that several other companies are also delving into brain-machine interfaces. Synchron, for instance, secured FDA approval for human trials in 2021, illustrating the growing interest and investment in this transformative field.
The Pentagon’s involvement in funding research on the military applications of such technology further emphasizes the broader implications and potential societal impact of brain-machine interface devices. As Neuralink ventures into human trials, the tech world awaits the results, keeping a keen eye on the promise and potential pitfalls of this groundbreaking technology.
Read Also: Stream ‘Vanderpump Rules’ Season 11 Premiere Online Now!
